Neuphoria Therapeutics Inc.NEUP決算レポート
Nasdaq
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
What changed in Neuphoria Therapeutics Inc.'s 6-K — 2022 vs 2023
No meaningful paragraph-level changes detected in the compared sections. Either the two filings are nearly identical or the sections did not parse.